Corrie, P. G., Marshall, A., Nathan, P. D., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C. G., Marples, M., Danson, S. J., Marshall, E., Houston, S. J., Board, R. E., Waterston, A. M., Nobes, J. P., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A., Westwell, S., Casasola, R., Chao, D., Maraveyas, A., Patel, P. M., Ottensmeier, C. H., Farrugia, D., Humphreys, A., Eccles, B., Young, G., Barker, E. O., Harman, C., Weiss, M., Myers, K. A., Chhabra, A., Rodwell, S. H., Dunn, J. A., & Middleton, M. R. (2019). adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of oncology, 30, 2013–2014. http://access.bl.uk/ark:/81055/vdc_100098455396.0x000027